Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Single-center, randomized, placebo-controlled study to: * characterize the subjects at baseline and discriminate groups of children based on IL-5, IL-17, IL-23 and INF-γ; * investigate the effect of Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) for nostril three times/day for 4 weeks, in comparison with placebo, in reducing nasal interleukin-5 (IL-5) in children with Allergic Rhinitis (AR). Secondary objectives are to examine the effect of resveratrol plus carboxymethyl-β-glucan, in comparison with placebo, on subjective parameters, i.e. symptom scores, visual analogue scales for rhinitis, quality of life and quality of sleep, and the effect on objective parameters, i.e. nasal nitric oxide (nNO) levels, nasal cytology and acoustic rhinometry.
Epistemonikos ID: 8b0dfc501169b40a239d63dda8d5c33098a54e0e
First added on: May 21, 2024